Mechanism of fluoroquinolone action

Current Opinion in Microbiology

Volumn 2, Issue 5, 1999, Pages 504-508

  Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; COMPLEX FORMATION; DNA CLEAVAGE; DNA REPLICATION; DRUG PROTEIN BINDING; ENZYME LOCALIZATION; GENE MUTATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DNA BINDING; REVIEW;

EID: 0032856370     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(99)00008-9     Document Type: Review

References (30)

1. Levine C, Hiasa H, Marians K DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta. 1400:1998;29-43. This excellent review provides an especially good overview of topoisomerase biochemistry, and an introduction to intracellular action and quinolone mechanism.
2. Critchlow SE, Maxwell A DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry. 35:1996;7387-7393.
3. Kampranis S, Maxwell A Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem. 273:1998;22606-22614. In this study with purified gyrase, ciprofloxacin is shown to alter the conformation of GyrB in quinolone/gyrase/DNA complexes in the absence of DNA cleavage. Also see [6].
4. Kampranis S, Maxwell A The DNA gyrase-quinolone complex, ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem. 173:1998;22615-22626. The ATPase activity of gyrase in the presence of ciprofloxacin is used to dissect formation of quinolone/gyrase/DNA complex formation using kinetic analyses. Also see [6].
5. Snyder M, Drlica K DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol. 131:1979;287-302.
6. Marians K, Hiasa H Mechanism of quinolone action: a drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem. 272:1997;9401-9409.
7. ••].
8. Zechiedrich EL, Christiansen K, Andersen A, Westergaard O, Osheroff N Double-stranded DNA cleavage/religation of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry. 28:1989;6229-6236.
9. Franco R, Drlica K DNA gyrase on the bacterial chromosome: oxolinic acid-induced DNA cleavage in the dnaA-gyrB region. J Mol Biol. 201:1988;229-233.
10. Khodursky A, Cozzarelli N The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem. 273:1998;27668-27677. This extensive physiological study of topoisomerase-IV-norfloxacin interactions provides evidence that topoisomerase IV acts behind replication forks. Use of gyrB and seqA mutants shows that topoisomerase IV-containing complexes can behave like gyrase-containing complexes by blocking replication immediately.
11. Adams D, Shekhtman E, Zechiedrich E, Schmid M, Cozzarelli N The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell. 71:1992;277-288.
12. Champoux JJ, Been MD Topoisomerases and the swivel problem. Alberts B Mechanistic Studies of DNA replication and Genetic recombination: ICN-UCLA Symposia on Molecular and Cellular Biology. 1980;809-815 Academic Press, New York.
13. Peter B, Ullsperger C, Hiasa H, Marians K, Cozzarelli N The structure of supercoiled intermediates in DNA replication. Cell. 94:1998;819-827. Using small bacterial plasmids, experimental support is provided for precatenanes forming behind replication forks.
14. Chen C-R, Malik M, Snyder M, Drlica K DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol. 258:1996;627-637.
15. Huang WM, Libbey J, VanderHoeven P, Yu SX Bipolar localization of Bacillus subtilis topoisomerase IV, an enzyme required for chromosome segregation. Proc Natl Acad Sci USA. 95:1998;4652-4657. Fluorescence microscopy is used to show that topoisomerase IV is localized to specific cellular regions.
16. Sinden RR, Pettijohn DE Chromosomes in living Escherichia coli cells are segregated into domains of supercoiling. Proc Natl Acad Sci USA. 78:1981;224-228.
17. Staczek P, Higgins NP Gyrase and topo IV modulate chromosome domain size in vivo. Mol Microbiol. 29:1998;1435-1448. Chromosome barriers to DNA slithering and branch migration were detected by failure of recombination between widely spaced res sites of γδ. Mutations in gyrase and topoisomerase IV increase the barriers.
18. Earnshaw WC, Heck MMS Localization of topoisomerase II in mitotic chromosomes. J Cell Biol. 100:1985;1716-1725.
19. Earnshaw WC, Halligan B, Cooke CA, Heck MMS, Liu LF Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol. 100:1985;1706-1715.
20. Burden DA, Osheroff N In vitro evolution of preferred topoisomerase II DNA cleavage sites. J Biol Chem. 274:1999;5227-5235. Nucleotide sequences likely to be preferred topoisomerase II cleavage sites were identified. This paper may guide similar studies with bacterial type II topoisomerases.
21. Hiasa H, Yousef D, Marians K DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J Biol Chem. 271:1996;26424-26429.
22. Hsiang YH, Lihou MG, Liu LF Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
23. Goss W, Deitz W, Cook T Mechanism of action of nalidixic acid on Escherichia coli. II. Inhibition of deoxyribonucleic acid synthesis. J Bacteriol. 89:1965;1068-1074.
24. Deitz WH, Cook TM, Goss WA Mechanism of action of nalidixic acid on Escherichia coli. III. Conditions required for lethality. J Bacteriol. 91:1966;768-773.
25. Zhao X, Xu C, Domagala J, Drlica K DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA. 94:1997;13991-13996.
26. Khodursky AB, Zechiedrich EL, Cozzarelli NR Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA. 92:1995;11801-11805.
27. Willmott CJ, Maxwell A A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother. 37:1993;126-127.
28. Pruss G, Franco R, Chevalier S, Manes S, Drlica K Effects of DNA gyrase inhibitors in Escherichia coli topoisomerase I mutants. J Bacteriol. 168:1986;276-282.
29. Morais Cabral JHM, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC Crystal structure of the breakage-reunion domain of DNA gyrase. Nature. 388:1997;903-906.
30. Dong Y, Zhao X, Domagala J, Drlica K Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother. 43:1999;1756-1758. A complex relationship between quinolone concentration and recovery of resistant mutants is described that allows fluoroquinolones of different structure to be compared. Introduced is mutant prevention concentration (MPC), a concept that can help prevent the selection of resistance during antibiotic therapy.